Literature DB >> 2532171

Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy.

H Martikainen1, J Penttinen, I Huhtaniemi, A Kauppila.   

Abstract

Ovarian granulosa cell tumor lung metastases regressed, and symptoms were relieved, during gonadotropin-releasing hormone (GnRH) agonist analog therapy after the failure of operative treatment and cytotoxic chemotherapy, indicating the hormone dependence of the malignancy. The response was transient, but the largest metastasis did not relapse. This case report suggests that GnRH analogs may offer a new approach to the treatment of ovarian stromal cell malignancies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532171     DOI: 10.1016/0090-8258(89)90089-9

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature.

Authors:  Dirkje W Sommeijer; Katrin M Sjoquist; Michael Friedlander
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 2.  Recent advances in granulosa cell tumor ovary: a review.

Authors:  Vijaykumar Dehannathparambil Kottarathil; Michelle Aline Antony; Indu R Nair; Keechilat Pavithran
Journal:  Indian J Surg Oncol       Date:  2012-12-07

3.  Ovarian granulosa cell tumors: a retrospective study of 27 cases and a review of the literature.

Authors:  Sakina Sekkate; Mouna Kairouani; Badr Serji; Adnane Tazi; Hind Mrabti; Saber Boutayeb; Hassan Errihani
Journal:  World J Surg Oncol       Date:  2013-06-18       Impact factor: 2.754

4.  Noninvasive test for the diagnosis of ovarian hormone-secreting-neoplasm in postmenopausal women.

Authors:  Ilan Cohen; Dan Nabriski; Ami Fishman
Journal:  Gynecol Oncol Rep       Date:  2015-06-10

5.  GnRHa as a treatment for letrozole-resistant recurrent adult granulosa cell tumors: A case report.

Authors:  Yuan Zhuang; Shushan Zhang; Yao Liu; Hua Yang
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.